# A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac

Source: https://onco.cc/trials/nct06742996/  
OnCo record `nct06742996` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Sonrotoclax, Zanubrutinib in mantle cell lymphoma, run by BeOne Medicines, now recruiting.

## Summary

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) is a phase 3 interventional study registered as NCT06742996 by BeOne Medicines, with 300 participants planned, started 2025-03-05 and due to reach its primary completion in 2028-08-31. Interventions recorded: Sonrotoclax, Zanubrutinib, Placebo. Conditions listed: Mantle Cell Lymphoma, B Cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06742996
- Phase: 3
- Setting: A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
- Sponsor: BeOne Medicines
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT06742996: https://clinicaltrials.gov/study/NCT06742996

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [Sonrotoclax](https://onco.cc/drugs/sonrotoclax/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct06742996.json